Autigen Announces Collaboration with Boehringer Ingelheim
Innovation 2 Enterprise
APRIL 18, 2022
Collaboration and licensing agreement to advance novel therapies for sensorineural hearing loss (SNHL), where there are currently no approved pharmacological therapies. After a joint research collaboration phase, Boehringer Ingelheim will be responsible for further preclinical and clinical development, and commercialization.
Let's personalize your content